AbbVie, Morphic ally in fibrosis
AbbVie Inc. and Morphic Therapeutic Inc. are teaming up to develop the latter’s oral integrin candidates for fibrosis-related indications, potentially including non-alcoholic steatohepatitis (NASH).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.